May 14, 2019 / 12:30AM GMT
Operator
Good day, and welcome to the Mayne Pharma Market Update Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Scott Richards, Chief Executive Officer of Mayne Pharma Group Limited. Please go ahead, sir.
Scott Anthony Richards - Mayne Pharma Group Limited - MD, CEO & Executive Director
Thank you, and good morning, everybody. And thanks for joining us on today's update call on short notice. With me today is Nick Freeman, our group CFO. To begin with, I'll provide a high-level overview of our trading performance this half, and our outlook into fiscal 2020, followed by an update on our strategy to rebalance our portfolio towards sustainable and [hormone growth] therapeutic categories and channels. And then we will take your questions. While the performance for the 10 months ending April 30 was stronger than the prior corresponding period at the [thousand] gross profit level, we faced a tough start in the second half in our generics product division. At a group level, revenue for the first 4 months of this
Q3 2019 Mayne Pharma Group Ltd Trading Update Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot